Q32 Bio (QTTB) Equity Average (2018 - 2026)

Q32 Bio's Equity Average history runs 9 years deep, the most recent figure standing at $44.2 million for Q1 2026.

• In Q1 2026, Equity Average rose 5217.7% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $44.2 million (up 5217.7% YoY), while the FY2025 annual figure was $23.8 million, up 126.91% from the prior year.
• Equity Average was $44.2 million for Q1 2026 at Q32 Bio, up from $11.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $253.3 million in Q2 2022 to a low of -$169.7 million in Q4 2023.
• Historically, Equity Average has averaged $11.0 million across 5 years, with a median of $11.8 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Equity Average slumped 533.15% in 2023, then jumped 5217.7% in 2026.
• A 5-year view of Equity Average shows it stood at $39.2 million in 2022, then plunged by 533.15% to -$169.7 million in 2023, then soared by 107.06% to $12.0 million in 2024, then retreated by 1.69% to $11.8 million in 2025, then jumped by 274.81% to $44.2 million in 2026.
• The last three Equity Average figures came in at $44.2 million (Q1 2026), $11.8 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.